Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis.

Onishi Y, Oura T, Takeuchi M

Diabetes therapy : research, treatment and education of diabetes and related disorders4 Feb 2024Cited by 4 (Europe PMC)

PMID38310163PMCIDPMC10942919DOI10.1007/s13300-024-01534-5PepBankPUB-38310163

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D, tirzepatide produced lower composite metabolic abnormality prevalence than dulaglutide at week 52.
In plain wordsIn Japanese patients with T2D, tirzepatide produced fewer composite metabolic abnormalities than dulaglutide.
Peptide
Tirzepatide
Outcome
DecreaseComposite metabolic abnormality prevalence
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
5 mg · 52 weeksAs given in this study (human).
Measurements
Composite endpoint prevalence
31.7%
Tirzepatide 5 mg at week 52
Composite endpoint prevalence
56.5%
Dulaglutide at week 52
Source sentences
Summary
At week 52, the proportion of participants on treatment that met the composite endpoint was 31.7%, 23.0%, and 14.2% in the tirzepatide 5-, 10-, and 15-mg arms, respectively, and 56.5% in the dulaglutide arm (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled, parallel-group, phase 3 trial that compared the efficacy and safety of tirzepatide monotherapy (5, 10, and 15 mg) to dulaglutide 0.75 mg in Japanese patients with T2D.
Report a problemFND-3831016301
02HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D, tirzepatide produced lower composite metabolic abnormality prevalence than dulaglutide at week 52.
In plain wordsIn Japanese patients with T2D, tirzepatide produced fewer composite metabolic abnormalities than dulaglutide.
Peptide
Tirzepatide
Outcome
DecreaseComposite metabolic abnormality prevalence
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
10 mg · 52 weeksAs given in this study (human).
Measurements
Composite endpoint prevalence
23%
Tirzepatide 10 mg at week 52
Composite endpoint prevalence
56.5%
Dulaglutide at week 52
Source sentences
Summary
At week 52, the proportion of participants on treatment that met the composite endpoint was 31.7%, 23.0%, and 14.2% in the tirzepatide 5-, 10-, and 15-mg arms, respectively, and 56.5% in the dulaglutide arm (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled, parallel-group, phase 3 trial that compared the efficacy and safety of tirzepatide monotherapy (5, 10, and 15 mg) to dulaglutide 0.75 mg in Japanese patients with T2D.
Report a problemFND-3831016302
03HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D, tirzepatide produced lower composite metabolic abnormality prevalence than dulaglutide at week 52.
In plain wordsIn Japanese patients with T2D, tirzepatide produced fewer composite metabolic abnormalities than dulaglutide.
Peptide
Tirzepatide
Outcome
DecreaseComposite metabolic abnormality prevalence
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
15 mg · 52 weeksAs given in this study (human).
Measurements
Composite endpoint prevalence
14.2%
Tirzepatide 15 mg at week 52
Composite endpoint prevalence
56.5%
Dulaglutide at week 52
Source sentences
Summary
At week 52, the proportion of participants on treatment that met the composite endpoint was 31.7%, 23.0%, and 14.2% in the tirzepatide 5-, 10-, and 15-mg arms, respectively, and 56.5% in the dulaglutide arm (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled, parallel-group, phase 3 trial that compared the efficacy and safety of tirzepatide monotherapy (5, 10, and 15 mg) to dulaglutide 0.75 mg in Japanese patients with T2D.
Report a problemFND-3831016303
04HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D, dulaglutide produced higher composite metabolic abnormality prevalence than tirzepatide 5 mg at week 52.
In plain wordsIn Japanese patients with T2D, dulaglutide produced more composite metabolic abnormalities than tirzepatide 5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseComposite metabolic abnormality prevalence
Study
n: not reported in source
Comparator
Tirzepatide 5 mg
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
0.75 mg · 52 weeksAs given in this study (human).
Measurements
Composite endpoint prevalence
56.5%
Dulaglutide at week 52
Source sentences
Summary
At week 52, the proportion of participants on treatment that met the composite endpoint was 31.7%, 23.0%, and 14.2% in the tirzepatide 5-, 10-, and 15-mg arms, respectively, and 56.5% in the dulaglutide arm (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled, parallel-group, phase 3 trial that compared the efficacy and safety of tirzepatide monotherapy (5, 10, and 15 mg) to dulaglutide 0.75 mg in Japanese patients with T2D.
Report a problemFND-3831016304
05HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D, dulaglutide produced higher composite metabolic abnormality prevalence than tirzepatide 10 mg at week 52.
In plain wordsIn Japanese patients with T2D, dulaglutide produced more composite metabolic abnormalities than tirzepatide 10 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseComposite metabolic abnormality prevalence
Study
n: not reported in source
Comparator
Tirzepatide 10 mg
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
0.75 mg · 52 weeksAs given in this study (human).
Measurements
Composite endpoint prevalence
56.5%
Dulaglutide at week 52
Source sentences
Summary
At week 52, the proportion of participants on treatment that met the composite endpoint was 31.7%, 23.0%, and 14.2% in the tirzepatide 5-, 10-, and 15-mg arms, respectively, and 56.5% in the dulaglutide arm (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled, parallel-group, phase 3 trial that compared the efficacy and safety of tirzepatide monotherapy (5, 10, and 15 mg) to dulaglutide 0.75 mg in Japanese patients with T2D.
Report a problemFND-3831016305
06HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D, dulaglutide produced higher composite metabolic abnormality prevalence than tirzepatide 15 mg at week 52.
In plain wordsIn Japanese patients with T2D, dulaglutide produced more composite metabolic abnormalities than tirzepatide 15 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseComposite metabolic abnormality prevalence
Study
n: not reported in source
Comparator
Tirzepatide 15 mg
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
0.75 mg · 52 weeksAs given in this study (human).
Measurements
Composite endpoint prevalence
56.5%
Dulaglutide at week 52
Source sentences
Summary
At week 52, the proportion of participants on treatment that met the composite endpoint was 31.7%, 23.0%, and 14.2% in the tirzepatide 5-, 10-, and 15-mg arms, respectively, and 56.5% in the dulaglutide arm (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled, parallel-group, phase 3 trial that compared the efficacy and safety of tirzepatide monotherapy (5, 10, and 15 mg) to dulaglutide 0.75 mg in Japanese patients with T2D.
Report a problemFND-3831016306
07HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D, composite metabolic abnormality prevalence decreased across all BMI subgroups treated with tirzepatide.
In plain wordsIn Japanese patients with T2D, composite metabolic abnormalities decreased from baseline across all BMI groups treated with tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseComposite endpoint across BMI subgroups
Study
n: not reported in source
Comparator
Baseline
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
5, 10, and 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
with reductions observed across all BMI subgroups treated with tirzepatide.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled, parallel-group, phase 3 trial that compared the efficacy and safety of tirzepatide monotherapy (5, 10, and 15 mg) to dulaglutide 0.75 mg in Japanese patients with T2D.
Report a problemFND-3831016307
08HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D, individual metabolic abnormalities showed trends similar to the composite endpoint, favoring tirzepatide over dulaglutide.
In plain wordsIn Japanese patients with T2D, individual metabolic abnormality trends favored tirzepatide over dulaglutide, like the composite endpoint.
Peptide
Tirzepatide
Outcome
DecreaseIndividual metabolic abnormality trends
Study
n: not reported in source
Comparator
Dulaglutide
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
5, 10, and 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
The proportion of participants with individual metabolic abnormalities showed similar trends to those observed for the composite endpoint.
2 context sentences(design, population, supporting numbers)
Summary · context
Tirzepatide was consistently superior to dulaglutide across all assessments.
Summary · context
This was a post hoc analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled, parallel-group, phase 3 trial that compared the efficacy and safety of tirzepatide monotherapy (5, 10, and 15 mg) to dulaglutide 0.75 mg in Japanese patients with T2D.
Report a problemFND-3831016308
09HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D, individual metabolic abnormalities were more prevalent with dulaglutide than with tirzepatide, as with the composite endpoint.
In plain wordsIn Japanese patients with T2D, dulaglutide had less favorable individual metabolic abnormality trends than tirzepatide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseIndividual metabolic abnormality trends
Study
n: not reported in source
Comparator
Tirzepatide
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
0.75 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
The proportion of participants with individual metabolic abnormalities showed similar trends to those observed for the composite endpoint.
2 context sentences(design, population, supporting numbers)
Summary · context
Tirzepatide was consistently superior to dulaglutide across all assessments.
Summary · context
This was a post hoc analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled, parallel-group, phase 3 trial that compared the efficacy and safety of tirzepatide monotherapy (5, 10, and 15 mg) to dulaglutide 0.75 mg in Japanese patients with T2D.
Report a problemFND-3831016309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03861052

A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

Eli Lilly and Companyn = 6367 May 2019 to 31 Mar 2021

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 14 Apr 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC